PRODUCT OVERVIEW & PREBIOTIC SUPERIORITY

Xylooligosaccharide (XOS) is widely recognized as the "Next-Generation Super Prebiotic" and a premier functional soluble dietary fiber. It is naturally present in trace amounts in fruits, bamboo shoots, and honey, and is industrially produced via targeted enzymatic degradation of natural plant xylan.

Compared to conventional oligosaccharides (such as Inulin, FOS, and GOS), XOS exhibits significant physiological and physicochemical advantages:

Ultra-Low Effective Dosage: While FOS and inulin require 5.0g - 10.0g per day to elicit a prebiotic response (frequently causing abdominal distention, excessive flatulence, and diarrhea), XOS requires only 0.7g - 1.4g daily to stimulate significant bifidogenic growth.

Superior Thermal & Acid Stability: Extremely stable across a broad pH spectrum (pH 2.5 to 8.0) and heat-resistant up to 100 - 120 deg C. It withstands harsh gastric acid barrier transit and high-temperature food processing (such as beverage pasteurization, retort sterilization, and baking) without degradation.

Clean Sensory Profile: Provides 30% - 40% of the sweetness of sucrose with a clean, refreshing profile, zero lingering off-notes, and low water activity.

XOS Powder

Items	Specifications	Result
Appearance	white powder	Conform
Odor, Taste	Characteristic	Conform
Particle Size	98% pass 80mesh	Conform
Content	≥99.0%	99.37%
Loss on drying	≤1%	0.30%
Melting Point	165.0ºC~169ºC	167ºC
Heavy Metals	≤10 ppm	Conform
Pb	≤2 ppm	Conform
As	≤2 ppm	Conform
Benzene	Without Benzene	Not detected
Solvent Residue	Methanol≤3000ppm	Conform
Total Plate Count	≤1000cfu/g	Conform
Total Yeast & Mold	≤100 cfu/g	Conform
E. Coli	Negative	Negative
Salmonella	Negative	Negative
Staphylococcus aureus	Negative	Negative

CORE HEALTH BENEFITS & SCIENTIFIC MECHANISMS

Hyper-Selective Bifidogenic Proliferation: Because human gastric acid and pancreatic amylases cannot hydrolyze beta-1,4-glycosidic bonds, XOS traverses the upper digestive tract intact into the colon. It serves as an exclusive, high-affinity substrate for beneficial Bifidobacteria (particularly Bifidobacterium adolescentis and B. animalis subsp. lactis), multiplying beneficial colonies up to 10-fold while suppressing toxic coliforms like Clostridium perfringens.

SCFA Production & Dual Gut Motility Regulation: Colonic fermentation of XOS yields high concentrations of beneficial Short-Chain Fatty Acids (SCFAs, especially acetate and butyrate). This drops colonic pH:

For Constipation: Stimulates colonic peristalsis, increases osmotic fecal hydration, softens hard stool, and significantly relieves constipation in seniors and pregnant women.

For Chronic Diarrheal Dysbiosis: Normalizes gut mucosal integrity, reduces pathogen-induced inflammation, restores microbial biodiversity, and halts chronic loose stool episodes.

Glycemic Control & Healthy Lipid Metabolism: With an extremely low caloric value (~1.5 kcal/g) and a non-digestible matrix, XOS triggers zero postprandial blood glucose or insulin spikes. It retards intestinal lipid and cholesterol assimilation, helping reduce circulating serum triglycerides and low-density lipoprotein (LDL) levels.

Dental Protection & Anti-Cariogenic Activity: Oral streptococci (such as Streptococcus mutans) cannot metabolize XOS to synthesize lactic acid. Furthermore, when consumed alongside sucrose, XOS competitively inhibits glucosyltransferase enzymes, preventing the formation of water-insoluble sticky glucans on teeth, protecting tooth enamel, and curbing plaque accumulation.

What does xylooligosaccharide do?

1. Xylo-oligosaccharides (XOS) can promote the growth or activity of beneficial intestinal microorganisms to maintain host gastrointestinal health. Clinical studies have found that XOS can relieve constipation and improve gastrointestinal function in the elderly.
2. Xylo-oligosaccharides are absorbed and utilized by Bifidobacterium and fermented and degraded into short-chain fatty acids, bifid factors, antibiotics and other substances, which have a significant effect on improving intestinal function.

Intervention effect of XOS on chronic diarrhea. After ingesting XOS, patients with diarrhea have reduced diarrhea symptoms, improved lipid metabolism, increased intestinal flora diversity, and increased the abundance of beneficial bacteria.

3. It can effectively reduce blood sugar and blood lipids and has no side effects on the organism.

4. Xylo-oligosaccharides cannot be digested in the human oral cavity and cannot be utilized by oral microorganisms. Therefore, xylo-oligosaccharides as a sweetener do not affect oral hygiene. In addition, when xylo-oligosaccharides and sucrose exist at the same time, they can prevent sucrose from being synthesized by microorganisms and generate insoluble polymer glucose, preventing the enamel on the tooth surface from falling off, and playing a certain protective role.

CUSTOM FORMULATION PLATFORMS (OEM/ODM BLENDS)

Platform A: Clinical Synbiotic Gut Defense Stick-Packs High-Purity XOS (1000mg) + Bifidobacterium lactis (10 Billion CFU) + Lactobacillus acidophilus (5 Billion CFU) + Resistant Dextrin.

Platform B: Sugar-Free Cleanse & Weight-Management Drink Mix XOS (1500mg) + White Kidney Bean Extract (Phaseolamin) + Green Tea EGCG + Apple Cider Vinegar Powder.

Platform C: Pediatric & Maternal Gentle Regularity Chewables XOS Powder (700mg) + Vitamin C (Acerola Cherry) + Zinc Citrate + Natural Strawberry Juice Powder.

Platform D: Tooth-Friendly Dental Lozenges & Sugar-Free Confectionery XOS Powder (30%) + Xylitol (65%) + Menthol + Zinc Lactate.

What is xylooligosaccharide used for?

1. Xylooligosaccharide can be used in products that can moisten the intestines and relieve constipation
2. It is used in nutrition and dietary supplement products
3. Used in products that can lower blood sugar and blood lipids
4. Used in products that can lower blood sugar and blood lipids

Reference

[1]. CHILDS C E,ＲYTI H,ALHONIEMI E,et al． Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalissubsp． lactis induce bifidogenesis and modulate markers of immunefunction in heATLhy adults: A double-blind,placebo-controlled,randomised,factorial cross-over study［J］． British Journal of Nutrition,2014,111( 11) : 1 945 － 1 956．

[2]. LICHT T R,EBERSBACH T,FRØKIÆRB H,et al.Prebiotics for prevention of gut infections[J].Trends in Food Science & Technology,2012(2)：70-82.

XOS Powder